JCO:发现I期肺腺癌复发独立预后因素
2013-01-07 JCO dxy ecoliDH5
愈来愈多的证据表明,对于器官恶性实体瘤患者,肿瘤浸润免疫细胞具有预后价值。为此,美国纪念斯隆凯特琳癌症中心的Prasad S. Adusumilli博士等人进行了一项研究,该研究对I期肺腺癌(ADC)患者免疫微环境的预后价值进行了考察。这项研究结果发表于2012年12月26日在线出版的《临床肿瘤学杂志》(Journal of Clinical
愈来愈多的证据表明,对于器官恶性实体瘤患者,肿瘤浸润免疫细胞具有预后价值。为此,美国纪念斯隆凯特琳癌症中心的Prasad S. Adusumilli博士等人进行了一项研究,该研究对I期肺腺癌(ADC)患者免疫微环境的预后价值进行了考察。这项研究结果发表于2012年12月26日在线出版的《临床肿瘤学杂志》(Journal of Clinical Oncology)上。
研究人员面向一个由956例I期肺腺癌患者组成的均衡队列(训练组与验证组各478例),通过组织芯片以及免疫组化法,对癌巢和肿瘤相关间质中存在的8类肿瘤浸润免疫细胞以及在肿瘤中5类细胞因子的表达情况进行了考察。
研究人员发现,尽管高含量的间质叉头框蛋白P3 (FoxP3)阳性细胞与较短的无复发生存期概率(RFP)间存在关联( P = .043),但是,更强的复发预测因素却是间质FoxP3与CD3间的相对比值(高比值5年RFP为 85% v 低比值5年RFP为77%; P = .004)。肿瘤白介素-12受体β2 (IL-12Rβ2)高表达与较好的预后间存在关联(高表达5年RFP为90% v低表达5年RFP为80%; P = .026),而肿瘤IL-7R高表达则与较差预后间存在关联(高表达5年RFP为76% v低表达5年RFP为86%; P = . 001)。多变量分析表明,此类免疫指标为与复发相关的独立因素。此外,尽管IL-7R仍是较差整体生存率的显著因素,但对IA与IB期以及瘤体≤ 2 cm的患者而言,所有指标都可作为与复发相关的预后因素。
该项研究不仅证实了I期ADC患者肿瘤免疫微环境所具有的生物学与预后意义,并且为其在临床预后分层以及免疫治疗干预中的应用提供了支持。
与肺腺癌相关的拓展阅读:
- 肺腺癌新分类:各学科不同视角
- Cancer:基因KRAS突变与晚期肺腺癌患者更短存活相关联
- Cancer Res.:阻断异位表达ATP合成酶抑制肺腺癌增殖
- Nat Med:日美发现引发肺腺癌异常融合基因KIF5B-RET
- 晚期肺腺癌综合治疗1例 更多信息请点击:有关肺腺癌更多资讯
Purpose Mounting evidence suggests that tumor-infiltrating immune cells have prognostic value for patients with solid organ malignancies. Our aim was to investigate the prognostic significance of the immune microenvironment in patients with stage I lung adenocarcinoma (ADC).
Patients and Methods Using tissue microarray and immunohistochemistry, we investigated eight types of tumor-infiltrating immune cells in the tumor nest and tumor-associated stroma as well as tumor expression of five cytokines in a uniform cohort of 956 patients with stage I lung ADC (478 each in training and validation cohorts).
Results Although a high density of stromal forkhead box P3 (FoxP3) –positive cells was associated with shorter recurrence-free probability (RFP; P = .043), the relative proportion of stromal FoxP3 to CD3 was a stronger predictor of recurrence (5-year RFP, 85% for high v 77% for low ratio; P = .004). High expression of tumor interleukin-12 receptor β2 (IL-12Rβ2) was associated with better outcome (5-year RFP, 90% for high v 80% for low expression; P = .026), whereas high expression of tumor IL-7R was associated with worse outcome (5-year RFP, 76% for high v 86% for low expression; P = .001). In multivariate analysis, these immune markers were independently associated with recurrence. Although IL-7R remained significant for poor overall survival, all the markers remained prognostic for recurrence in patients with stages IA and IB disease as well as for patients with tumors ≤ 2 cm.
Conclusion Our investigation confirms the biologic and prognostic significance of the tumor immune microenvironment for patients with stage I lung ADC and provides support for its use to stratify clinical outcome and immunotherapeutic interventions.
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
#JCO#
66
#预后因素#
64